Economic Burden

In patients with relapsed or refractory LBCL treated with lisocabtagene maraleucel, post-infusion monitoring costs were lower in the outpatient setting versus the inpatient setting Read More ›

Claims-based analysis assesses healthcare resource utilization and standard-of-care costs among US patients with relapsed or refractory MCL Read More ›

Medicare Advantage claims analysis explores economic burden of cancer by type and stage, underscoring the importance of early detection Read More ›

Conference Correspondent Coverage is Brought to You by the Publishers of:
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications